enGene Holdings Inc. (NASDAQ:ENGN) Receives Consensus Rating of “Buy” from Brokerages

enGene Holdings Inc. (NASDAQ:ENGN) has been assigned an average recommendation of “Buy” from the seven analysts that are presently covering the stock, Marketbeat.com reports. Seven equities research analysts have rated the stock with a buy recommendation. The average 1-year price target among analysts that have issued a report on the stock in the last year is $33.67.

Separately, Oppenheimer began coverage on enGene in a report on Wednesday, August 28th. They issued an “outperform” rating and a $30.00 price target for the company.

enGene Trading Down 3.7 %

ENGN opened at $6.72 on Wednesday. The business’s fifty day simple moving average is $7.86 and its 200 day simple moving average is $11.91. enGene has a 52 week low of $4.94 and a 52 week high of $43.00. The company has a quick ratio of 42.80, a current ratio of 42.80 and a debt-to-equity ratio of 0.09.

enGene (NASDAQ:ENGN) last issued its quarterly earnings results on Friday, June 14th. The company reported ($0.38) EPS for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.14). As a group, equities analysts predict that enGene will post -1.49 EPS for the current year.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in ENGN. Logos Global Management LP lifted its stake in shares of enGene by 50.0% in the 2nd quarter. Logos Global Management LP now owns 1,200,000 shares of the company’s stock valued at $11,316,000 after purchasing an additional 400,000 shares in the last quarter. SR One Capital Management LP acquired a new stake in enGene in the 2nd quarter valued at $4,715,000. Janus Henderson Group PLC purchased a new position in enGene in the first quarter valued at about $17,095,000. Altitude Crest Partners Inc. acquired a new position in shares of enGene during the first quarter worth about $2,039,000. Finally, Omega Fund Management LLC purchased a new stake in shares of enGene during the 4th quarter valued at about $10,441,000. 64.16% of the stock is owned by hedge funds and other institutional investors.

enGene Company Profile

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.